Original Article
Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy
N Engl J Med 1998; 338:1663-1671June 4, 1998
- Abstract
Background
Children with high-risk acute lymphoblastic leukemia (ALL) who have a slow response to initial chemotherapy (more than 25 percent blasts in the bone marrow on day 7) have a poor outcome despite intensive therapy. We conducted a randomized trial in which such patients were treated with either an augmented intensive regimen of post-induction chemotherapy or a standard regimen of intensive post-induction chemotherapy.
Methods
Between January 1991 and June 1995, 311 children with newly diagnosed ALL who were either 1 to 9 years of age with white-cell counts of at least 50,000 per cubic millimeter or 10 years of age or older, had a slow response to initial therapy, and entered remission at the end of induction chemotherapy were randomly assigned to receive standard therapy (156 children) or augmented therapy (155). Those with lymphomatous features were excluded. Event-free survival and overall survival were assessed from the end of induction treatment.
Results
The outcome at five years was significantly better in the augmented-therapy group than in the standard-therapy group (Kaplan–Meier estimate of event-free survival [±SD]: 75.0±3.8 vs. 55.0±4.5 percent, P<0.001; overall survival: 78.4±3.7 vs. 66.7±4.2 percent, P=0.02). The difference between treatments was most pronounced among patients one to nine years of age, all of whom had white-cell counts of at least 50,000 per cubic millimeter (P<0.001). Risk factors for an adverse event in the entire cohort included a white-cell count of 200,000 per cubic millimeter or higher (P=0.004), race other than black or white (P<0.001), and the presence of a t(9;22) translocation (P=0.007). The toxic effects of augmented therapy were considerable but manageable.
Conclusions
Augmented post-induction chemotherapy results in an excellent outcome for most patients with high-risk ALL and a slow response to initial therapy.
Media in This Article
Figure 1
Event-free Survival during Five Years of Follow-up in Patients with ALL, According to the Type of Post-Induction Chemotherapy.Figure 2
Event-free Survival during Five Years of Follow-up in Patients with ALL Who Received Standard Therapy or Augmented Therapy, According to Age and White-Cell Count at Diagnosis.Article Activity
- Article
In children with acute lymphoblastic leukemia (ALL) who are older than one year of age, certain presenting features, such as a white-cell count above 50,000 per cubic millimeter,1-3 an age of 10 years or older,4,5 the presence of bulky disease,1,3,6 T-cell–lineage immunophenotype,7-9 and various chromosomal translocations,10-16 carry an increased risk of treatment failure. The outcome for most of these children has improved with the use of intensive chemotherapy after the induction of remission,17-22 but approximately 30 percent of such high-risk patients eventually relapse.
Numerous studies have demonstrated that a rapid response to initial chemotherapy is an important prognostic factor in childhood ALL.17,18,23-28 German investigators observed that patients with fewer than 1000 blasts per cubic millimeter in the peripheral blood after a seven-day course of prednisone had significantly bette r event-free survival than patients with 1000 or more blasts per cubic millimeter.17,28,29 Similarly, we reported that children with 25 percent blasts or fewer in the bone marrow on day 7 had a better response to initial chemotherapy (three-year event-free survival, 77 percent) than those with more than 25 percent blasts (three-year event-free survival, 48 percent).26 In an attempt to improve the outcome for children with a slow response to initial therapy, we developed a strategy of augmented, intensive post-induction chemotherapy that was based on previous successful regimens for ALL.30-32 This approach appeared promising in a nonrandomized pilot study.33 We now report on a randomized comparison of augmented therapy with standard intensive post-induction therapy in children with high-risk ALL who entered remission after a slow response to initial therapy.
Methods
Patients
Children and adolescents with newly diagnosed ALL who were 1 to 9 years of age and had white-cell counts of at least 50,000 per cubic millimeter or who were 10 years of age or older were enrolled between January 1991 and June 1995. Those with lymphomatous features6 were excluded. Diagnosis was based on morphologic, biochemical, and immunologic features of leukemic cells, including lymphoblast morphology as determined by Wright–Giemsa staining, negative staining for myeloperoxidase, and reactivity with monoclonal antibodies to lymphoid differentiation antigens associated with B-cell or T-cell lineage, as described previously.34 Patients with slow initial responses (>25 percent marrow blasts on day 7) who had entered remission by day 28 were randomly assigned at the end of induction therapy to receive standard or augmented therapy.
Treatment Protocol
All patients received identical five-week courses of induction chemotherapy, as previously described.33 The post-induction regimens are given in Table 1Table 1
The Standard-Therapy and Augmented-Therapy Regimens.. During the first year of post-induction therapy, the augmented regimen included more vincristine, asparaginase, methotrexate, and dexamethasone than the standard regimen, although the standard regimen included more oral methotrexate, prednisone, and mercaptopurine. Therapy was continued for two years for girls and for three years for boys, beginning with the first interim maintenance period (Table 1)35 (and unpublished data). Presymptomatic central nervous system therapy consisted of intrathecal methotrexate and cranial radiation. This protocol was approved by the National Cancer Institute and the institutional review boards of the participating institutions. Informed consent was obtained from the patients, their parents, or both, as deemed appropriate, according to Department of Health and Human Services guidelines.Study Design and Statistical Analysis
Balanced block randomization was used to ensure that approximately equal numbers of patients were randomly assigned to each regimen. The study was monitored by an independent data-monitoring committee and followed a monitoring plan that was based on group sequential monitoring boundaries36 that required analysis of results at six-month intervals for a maximum of 10 analyses. With a target enrollment of 296 randomized patients, we estimated that the study had a power of approximately 81 percent at the final analysis to detect a change in five-year event-free survival from 45 percent to 62 percent or more with a two-sided log-rank test (alpha level, 0.05). The monitoring boundary was crossed in July 1996 (the ninth planned data analysis), and at that time study results were released.
This analysis was performed in December 1997. Similarities between patients in the two groups were assessed with chi-square tests for homogeneity of proportions. Outcome analyses used life-table methods and associated statistics. The primary end point examined was event-free survival from the time of randomization. The events considered were relapse at any site, death during remission, or a second malignant neoplasm, whichever occurred first. Data on patients who had not had an event at the time of the analysis were censored in the analysis of event-free survival at the time of the last contact with them. Life-table estimates were calculated by the Kaplan–Meier procedure, and the standard deviation of the life-table estimate was obtained with Greenwood's formula.37 The Kaplan–Meier estimates (±SD) are presented for either the first five years or the first three years after randomization, depending on the number of patients in the follow-up. Ninety-five percent confidence intervals can be approximated as the life-table estimates ±1.96 SD. The log-rank statistic was used to compare patterns of event-free survival and overall survival in the groups.38,39 Comparisons of randomized treatment regimens were performed according to the intention-to-treat method. Stratified log-rank tests were also used to adjust for the possible modifying effect of other factors on the comparison of interest.40 An adjusted Cox regression analysis was used to determine the influence of prognostic factors on the primary treatment effect. Life-table analyses of the effect of isolated central nervous system and marrow relapses on the results with each regimen were compared with the log-rank statistic. Life-table analysis of the relative risk of an adverse event was calculated with the log-rank ratio of observed events to expected events.41
Results
Patients
A total of 1136 patients were enrolled. Three patients died before day 7, and marrow was not obtained on day 7 from 15 patients. Of the remaining 1118 patients, 360 (32 percent) had slow responses to initial therapy. Of these, 340 (94 percent) entered remission after induction therapy, 19 did not enter remission after induction therapy, and 1 received modified induction therapy and therefore was deemed ineligible. Of the 340 eligible patients, 317 (93 percent) underwent randomization. A subsequent review revealed that 6 of these patients did not have a slow response; thus, 311 patients were eligible for the study. Of these, 156 were assigned to standard therapy and 155 were assigned to augmented therapy.
The characteristics of the patients in the two groups are shown in Table 2Table 2
Characteristics of the Patients at Diagnosis.. There were no significant differences between the groups. Most patients were at least 10 years of age, and approximately half had white-cell counts of at least 50,000 per cubic millimeter. Centrally reviewed cytogenetic data on translocations associated with a high risk of an adverse event were available for 91 of the patients: 3 patients had the t(4;11) translocation, 4 had t(1;19), and 7 had t(9;22). Among 209 patients with immunophenotypic data, 87.6 percent had ALL of B-cell lineage.Study Violations
Thirteen patients (seven in the standard-therapy group and six in the augmented-therapy group) received a bone marrow transplant during their first remission but were included in the intention-to-treat analysis. Indications for transplantation included the presence of a t(9;22) translocation (four patients), a white-cell count of more than 200,000 per cubic millimeter (three patients), virus-associated hemophagocytic syndrome (one patient), the presence of myeloid antigen (two patients), and other reasons (three patients). Two patients in the standard-therapy group and one patient in the augmented-therapy group refused cranial radiotherapy. Five patients assigned to augmented therapy did not receive the second cycle of delayed intensification therapy. Major changes in treatment were required for three patients assigned to standard therapy (two patients had fungal infections, and one had an elevation in aminotransferases) and five patients assigned to augmented therapy (three patients had elevations in aminotransferases, one had leukoencephalopathy, and one was not compliant with oral therapy).
Outcome of Treatment
At the time the study data were released in July 1996, the four-year event-free survival rate was significantly better among patients in the augmented-therapy group than among those in the standard-therapy group (75.4±4.0 vs. 57.2±4.5 percent, P=0.009, adjusted for multiple evaluations of the data). At that time the median follow-up for patients with event-free survival was 31 months (range, 1 to 63). When we reanalyzed the data in December 1997 after an additional follow-up period of approximately 1.5 years, 5-year event-free survival remained significantly better in the augmented-therapy group than in the standard-therapy group (75.0±3.8 vs. 55.0±4.5 percent, P<0.001) (Figure 1Figure 1
Event-free Survival during Five Years of Follow-up in Patients with ALL, According to the Type of Post-Induction Chemotherapy.). The median follow-up for patients with event-free survival was 49 months (range, 2 to 82 months). The difference in event-free survival was maintained (P<0.001) when patients who received a bone marrow transplant were censored at the time of transplantation. Overall survival at five years was also better in the augmented-therapy group than in the standard-therapy group (78.4±3.7 vs. 66.7±4.2 percent, P=0.02).There were 65 events in the standard-therapy group and 36 events in the augmented-therapy group (Table 3Table 3
Frequency and Type of Events among Patients Assigned to Standard or Augmented Therapy.). Isolated marrow relapse was the main cause of treatment failure for both regimens, occurring in 43 patients in the standard-therapy group and 30 patients in the augmented-therapy group (P= 0.004 by the log-rank test), whereas central nervous system relapses were more common among patients in the standard-therapy group (8 vs. 0, P=0.002 by the log-rank test). Seven patients in the standard-therapy group and four patients in the augmented-therapy group died while in remission.In all subgroups analyzed, the results were better among patients who received augmented therapy than among those who received standard therapy. The difference in outcome between groups was most pronounced for patients who were one to nine years of age, all of whom had high white-cell counts as dictated by the eligibility criteria, with five-year event-free survival of 41.7±8.4 percent in the standard-therapy group and 84.6±5.0 percent in the augmented-therapy group (P<0.001) (Figure 2AFigure 2
Event-free Survival during Five Years of Follow-up in Patients with ALL Who Received Standard Therapy or Augmented Therapy, According to Age and White-Cell Count at Diagnosis.) and a relative risk of an adverse event in the standard-therapy group of 4.6. For patients who were 10 or more years old with white-cell counts of at least 50,000 per cubic millimeter, the outcome was better after augmented therapy than after standard therapy (three-year event-free survival, 66.7±9.7 vs. 47.9±9.7 percent) (Figure 2B), with a relative risk of an adverse event of 1.7 in the standard-therapy group (P=0.21). Among patients who were 10 or more years old with white-cell counts below 50,000 per cubic millimeter, the five-year event-free survival rate was 73.3±5.7 percent in the augmented-therapy group and 66.2±5.8 percent in the standard-therapy group (relative risk of an adverse event, 1.26; P=0.45). Among 31 patients with white-cell counts of 200,000 per cubic millimeter or higher, event-free survival was better for those in the augmented-therapy group (relative risk of an adverse event in the standard-therapy group, 2.2; P=0.14).Augmented therapy improved the outcome for patients with ALL of either B-cell lineage or T-cell lineage. Estimates of five-year event-free survival for patients with B-cell–lineage ALL were 74.7±5.1 percent with augmented therapy and 52.2±5.9 percent with standard therapy (P=0.002). For patients with T-cell–lineage ALL, event-free survival at three years was 91.7±8.0 percent in the augmented-therapy group and 71.4±12.1 percent in the standard-therapy group (P=0.25). Furthermore, the outcome for patients with ALL of T-cell lineage was similar to that for patients with ALL of B-cell lineage, regardless of regimen.
Prognostic Factors
An analysis of prognostic factors for the entire cohort of patients indicated that most base-line characteristics did not influence event-free survival. However, a white-cell count of 200,000 per cubic millimeter or higher, race other than black or white, and the presence of a t(9;22) translocation were prognostically important. For patients with white-cell counts of at least 200,000 per cubic millimeter, three-year event-free survival was 47.4±9.1 percent, as compared with 72.4±2.7 percent for those with white-cell counts below 200,000 per cubic millimeter (P=0.004). Patients who were neither black nor white had a significantly increased risk of an adverse event, as compared with whites or blacks (five-year event-free survival, 51.2±6.0 percent vs. 69.4±3.4 percent; P<0.001). Patients with a t(9;22) translocation had a significantly increased risk of an adverse event, as compared with those without this translocation (three-year event-free survival, 28.6±17.1 percent vs. 73.6±4.8 percent; P=0.007).
Notably, of the seven patients with the Philadelphia chromosome, two of the three in the standard-therapy group and three of the four in the augmented-therapy group had events. Both patients with the Philadelphia chromosome who survived without an event (one in each group) received a bone marrow transplant while in first remission. A Cox regression analysis with adjustment for these and other common prognostic factors revealed no attenuation of the effect of treatment on the difference in outcome between the augmented-therapy and the standard-therapy groups (P=0.001).
Toxic Effects
The toxic effects of the two types of therapy are shown in Table 4Table 4
Toxic Effects of Standard and Augmented Therapy.. There was a higher frequency of allergic reactions to Escherichia coli asparaginase in the augmented-therapy group than in the standard-therapy group (64 vs. 4 reactions). The majority of the patients with allergic reactions (49 and 4, respectively) successfully continued asparaginase therapy after they were switched to erwinia asparaginase or polyethylene glycol asparaginase. Osteonecrosis developed in 20 patients in the augmented-therapy group and in 14 patients in the standard-therapy group; only 1 of these patients was under 10 years of age at the time of diagnosis. Life-table estimates for the occurrence of osteonecrosis at three years were 15.1 percent for the augmented-therapy group and 11.9 percent for the standard-therapy group (P=0.44). No cases had developed after three years of follow-up. The mean total duration of hospitalization was slightly longer for patients in the augmented-therapy group than in the standard-therapy group, primarily because of the additional time needed for the second cycles of interim maintenance and delayed intensification therapy (data not shown).Three patients in the augmented-therapy group died in remission as a result of toxicity: one died of acute respiratory distress syndrome, one of pulmonary toxicity, and one of Candida tropicalis infection; one patient in remission was murdered. Seven patients in the standard-therapy group died in remission. Four of these deaths were due to documented infection: aspergillosis in one patient, clostridium septicemia in one, hepatosplenic candidiasis in one, and infection with an unspecified gram-negative bacteria in one. Of the remaining three deaths, one was due to pulmonary hemorrhage, one was due to acute respiratory distress syndrome after a presumed infection, and one was due to unknown causes.
Discussion
We previously reported that among children with high-risk ALL, those with a rapid response to initial therapy (defined as the presence of no more than 25 percent blasts in the marrow on the seventh day of induction chemotherapy) had a better outcome than those with a slow response (more than 25 percent blasts).24,26,27 Other investigators also reported poor outcomes for patients with a slow response to prednisone or multiagent induction therapy.17,25,28,29 In this randomized trial of post-induction treatment of patients with a slow response, we found that the outcome with augmented treatment was superior to that with standard treatment (five-year event-free survival, 75 percent vs. 55 percent). In our nonrandomized pilot study of augmented therapy, the four-year event-free survival rate (±SD) was 70.8±4.6 percent.33 Furthermore, subsequent analysis of the pilot study revealed a six-year event-free survival rate of 65.4±4.9 percent, suggesting that the results of the randomized trial are unlikely to change significantly with longer follow-up. Our results also suggest that the degree of cytoreduction achieved after one to two weeks of induction chemotherapy is a useful indicator of the susceptibility of leukemic cells to chemotherapeutic drugs.
Augmented treatment significantly improved event-free survival overall (75.0±3.8 percent, as compared with 55.0±4.5 percent in the standard-therapy group). In all subgroups analyzed, augmented therapy resulted in improved event-free survival. The difference was significant in the subgroup of patients who were one to nine years of age, all of whom had high white-cell counts. There was a trend toward a better outcome among older patients. There was also a trend toward improved outcomes with augmented therapy in patients with ALL of either B-cell lineage or T-cell lineage. This finding is in agreement with our analysis, which demonstrated improved outcome for the entire cohort of children with T-cell–lineage ALL who were treated with Children's Cancer Group protocols between 1989 and 1995.34 Augmented therapy was ineffective for the seven patients with the Philadelphia chromosome. Five of these seven patients had events, and four of them ultimately died. The two patients who survived without events received a bone marrow transplant while in first remission. These data are consistent with recent data from European studies of children with ALL who have a poor response to initial prednisone therapy.42
The toxic effects of augmented therapy have been considerable, but they appear to be manageable. The most common long-term toxic effect was osteonecrosis, which occurred almost exclusively in adolescent patients.
We noted a significantly lower rate of central nervous system relapse in the augmented-therapy group than in the standard-therapy group. Since the patients assigned to each regimen received cranial radiotherapy and intrathecal therapy for presymptomatic treatment of the central nervous system, the benefit observed with augmented therapy may have been due to the use of intensified systemic therapy. Indeed, previous investigators have noted a similar effect with intensive systemic therapy.43-45
Although we do not know which components of augmented therapy were responsible for the improved outcome, we surmise that the effect is attributable to the increased dose intensities and prolonged duration of therapy. During the interim maintenance phase in the augmented-therapy regimen, repeated courses of vincristine, intravenous methotrexate, and asparaginase replaced the daily oral mercaptopurine and the weekly oral methotrexate used in the standard-therapy regimen. The augmented regimen also included an additional two weeks of nonmyelosuppressive therapy with vincristine and asparaginase during each consolidation or reconsolidation course and included both a second interim maintenance phase and a second course of delayed intensification.
A recent Children's Cancer Group study of intermediate-risk ALL showed that patients with a slow response had an improved outcome when treated with two courses of delayed intensification rather than one course,45 suggesting that prolonged therapy was important to the improved outcome with augmented therapy in the current study. We are attempting to distinguish the relative contributions of early increased dose intensity and a prolonged duration of therapy in a new therapeutic study of children with high-risk ALL.
Supported by grants from the National Institutes of Health (CA 13539, CA 02971, CA 17829, CA 05436, CA 10382, CA 20320, CA 03888, CA 02649, CA 03750, CA 03526, CA 36015, CA 26270, CA 26044, CA 07306, CA 11796, CA 42764, CA 13809, CA 10198, CA 29013, CA 26126, CA 14560, CA 27678, CA 29314, CA 28851, and CA 28882).
Source Information
From the Section of Pediatric Hematology–Oncology, University of Chicago, Chicago (J.B.N.); the Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles (H.N.S.); Group Operations Center, Children's Cancer Group, Arcadia, Calif. (H.N.S., M.G.S.); the Division of Pediatric Bone Marrow Transplantation, University of Iowa Hospital and Clinics, Iowa City (M.E.T.); the Department of Radiation Oncology, Long Beach Memorial Medical Center, Long Beach, Calif. (J.M.C.); the Department of Pediatric Hematology–Oncology, Vanderbilt University, Nashville (J.N.L.); the Department of Pediatric Hematology–Oncology, Oregon Health Sciences University, and Doernbecher Children's Hospital, Portland (L.W.); Children's Cancer Group Acute Lymphoblastic Leukemia Biology Reference Laboratory and Wayne Hughes Institute, St. Paul, Minn. (F.M.U.); and the Department of Pediatrics, University of Wisconsin, Madison (P.S.G.).
Address reprint requests to Dr. Nachman at the Children's Cancer Group, P.O. Box 60012, Arcadia, CA 91066-6012.
Appendix
The following institutions and principal investigators of the Children's Cancer Group participated in the study: Group Operations Center, Arcadia, Calif. — W. Bleyer, A. Khayat, H. Sather, M. Krailo, J. Buckley, D. Stram, R. Sposto; University of Michigan Medical Center, Ann Arbor — R. Hutchinson; University of California Medical Center, San Francisco — K. Matthay; University of Wisconsin Hospital, Madison — P. Gaynon; Children's Hospital and Medical Center, Seattle — R. Chard; Rainbow Babies and Children's Hospital, Cleveland — S. Shurin; Children's National Medical Center, Washington, D.C. — G. Reaman; Children's Hospital of Los Angeles, Los Angeles — J. Ortega; Children's Hospital of Columbus, Columbus, Ohio — F. Ruymann; Columbia Presbyterian College of Physicians and Surgeons, New York — S. Piomelli; Children's Hospital of Pittsburgh, Pittsburgh — J. Mirro; Vanderbilt University School of Medicine, Nashville — J. Lukens; Doernbecher Memorial Hospital for Children, Portland, Oreg. — L. Wolff; University of Minnesota Health Sciences Center, Minneapolis — W. Woods; Children's Hospital of Philadelphia, Philadelphia — A. Meadows; Memorial Sloan-Kettering Cancer Center, New York — P. Steinherz; James Whitcomb Riley Hospital for Children, Indianapolis — P. Breitfeld; University of Utah Medical Center, Salt Lake City — R. O'Brien; University of British Columbia, Vancouver — C. Fryer; Children's Hospital Medical Center, Cincinnati — R. Wells; Harbor–UCLA and Miller Children's Medical Center, Long Beach, Calif. — J. Finklestein; University of California Medical Center, Los Angeles — S. Feig; University of Iowa Hospitals and Clinics, Iowa City — R. Tannous; Children's Hospital of Denver, Denver — L. Odom; Mayo Clinic and Foundation, Rochester, Minn. — G. Gilchrist; Izaak Walton Killam Hospital for Children, Halifax, N.S. — D. Barnard; University of North Carolina, Chapel Hill — J. Wiley; University of Medicine and Dentistry of New Jersey, Camden — M. Donaldson; Children's Mercy Hospital, Kansas City, Mo. — M. Hetherington; University of Nebraska Medical Center, Omaha — P. Coccia; Wyler Children's Hospital, Chicago — J. Nachman; M.D. Anderson Cancer Center, Houston — B. Raney; Princess Margaret Hospital, Perth, Western Australia — D. Baker; New York University Medical Center, New York — A. Rausen; and Children's Hospital of Orange County, Orange, Calif. — M. Cairo.
- References
References
1
Lilleyman JS ,Eden OB . United Kingdom Medical Research Council Acute Lymphoblastic Leukaemia (UKALL) Trials I-VIII: clinical features and results of treatment in four groups of children with adverse prognostic features. Med Pediatr Oncol 1986;14:182-186
CrossRef | Medline2
Hammond D ,Sather H ,Nesbit M , et al. Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 1986;14:124-134
CrossRef | Medline3
Crist W ,Boyett J ,Pullen J ,van Eys J ,Vietti T . Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. Med Pediatr Oncol 1986;14:135-139
CrossRef | Medline4
Santana VM ,Dodge RK ,Crist WM , et al. Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia. Leukemia 1990;4:87-90
Web of Science | Medline5
Crist W ,Shuster J ,Look T , et al. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia: the Pediatric Oncology Group. Leukemia 1992;6:Suppl 2:162-166
Web of Science | Medline6
Steinherz PG ,Siegel SE ,Bleyer WA , et al. Lymphomatous presentation of childhood acute lymphoblastic leukemia: a subgroup at high risk of early treatment failure. Cancer 1991;68:751-758
CrossRef | Web of Science | Medline7
Garand R ,Bene MC . Incidence, clinical and laboratory features, and prognostic significance of immunophenotypic subgroups in acute lymphoblastic leukemia: the GEIL experience. Recent Results Cancer Res 1993;131:283-295
Medline8
Pullen DJ ,Sullivan MP ,Falletta JM , et al. Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). Blood 1982;60:1159-1168
Web of Science | Medline9
Pui CH ,Behm FG ,Singh B , et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990;75:174-179
Web of Science | Medline10
Pui CH ,Frankel LS ,Carroll AJ , et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 1991;77:440-447
Web of Science | Medline11
Pui CH . Acute leukemias with the t(4;11)(q21;q23). Leuk Lymphoma 1992;7:173-179
CrossRef | Web of Science | Medline12
Crist WM ,Carroll AJ ,Shuster JJ , et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1990;76:117-122
Web of Science | Medline13
Shikano T ,Kaneko Y ,Takazawa M ,Ueno N ,Ohkawa M ,Fujimoto T . Balanced and unbalanced 1;19 translocation-associated acute lymphoblastic leukemias. Cancer 1986;58:2239-2243
CrossRef | Web of Science | Medline14
Pui CH ,Raimondi SC ,Hancock ML , et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19)(q23;p13) or its derivative. J Clin Oncol 1994;12:2601-2606
Web of Science | Medline15
Bloomfield CD ,Goldman AI ,Alimena G , et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 1986;67:415-420
Web of Science | Medline16
Raimondi SC . Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993;81:2237-2251
Web of Science | Medline17
Reiter A ,Schrappe M ,Ludwig WD , et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-3133
Web of Science | Medline18
Schrappe M ,Reiter A ,Sauter S , et al. Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Die Bedeutung des initialen therapyieansprechens in Blut und Knochenmark. Klin Padiatr 1994;206:208-221
CrossRef | Web of Science | Medline19
Rivera GK ,Pinkel D ,Simone JV ,Hancock ML ,Crist WM . Treatment of acute lymphoblastic leukemia: 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-1295
Full Text | Web of Science | Medline20
Clavell LA ,Gelber RD ,Cohen HJ , et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315:657-663
Full Text | Web of Science | Medline21
Gaynon PS ,Bleyer WA ,Steinherz PG , et al. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features: report of Children's Cancer Study Group Study CCG-193P. Am J Pediatr Hematol Oncol 1988;10:42-50
CrossRef | Medline22
Steinherz PG ,Gaynon P ,Miller DR , et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen -- a new intensive therapy protocol: a report from the Childrens Cancer Study Group. J Clin Oncol 1986;4:744-752
Web of Science | Medline23
Sallan SE ,Camitta BM ,Cassady JR ,Nathan DG ,Frei E III . Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. Blood 1978;51:425-433
Web of Science | Medline24
Miller DR ,Leikin S ,Albo V ,Sather H ,Karon M ,Hammond D . Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141: a report from Childrens Cancer Study Group. Cancer 1983;51:1041-1049
CrossRef | Web of Science | Medline25
Gajjar A ,Ribeiro R ,Hancock ML , et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995;86:1292-1295
Web of Science | Medline26
Gaynon PS ,Bleyer WA ,Steinherz PG , et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990;18:273-279
CrossRef | Medline27
Steinherz PG ,Gaynon PS ,Breneman JC , et al. Cytoreduction and prognosis in acute lymphoblastic leukemia -- the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996;14:389-398
Web of Science | Medline28
Riehm H ,Reiter A ,Schrappe M , et al. Die Corticosteroid-abhängige Dezimierung der Leukamiezellzahl im Blut als Prognose faktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BMF 83). Klin Padiatr 1987;199:151-160
CrossRef | Web of Science | Medline29
Schrappe M ,Reiter A ,Riehm H . Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1996;14:2403-2406
Web of Science | Medline30
Henze G ,Langermann H-J ,Bramswig J , et al. Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen. Klin Padiatr 1981;193:145-154
CrossRef | Web of Science | Medline31
Tubergen D ,Gilchrist G ,O'Brien RT , et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 1993;11:527-537
Web of Science | Medline32
Pinkerton CR ,Mills S ,Chessells JM . Modified Capizzi maintenance regimen in children with relapsed acute lymphoblastic leukaemia. Med Pediatr Oncol 1986;14:69-72
CrossRef | Medline33
Nachman J ,Sather HN ,Gaynon PS ,Lukens JN ,Wolff L ,Trigg ME . Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997;15:2222-2230
Web of Science | Medline34
Uckun F ,Reaman G ,Steinherz PG , et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. Leuk Lymphoma 1996;24:57-70
CrossRef | Web of Science | Medline35
Childhood ALL Collaborative Group
CrossRef | Web of Science | Medline36
Fleming T ,Harrington D ,O'Brien P . Designs for group sequential tests. Contemp Clin Trials 1958;53:457-48137
Kaplan E ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science38
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline39
Peto R ,Pike MC ,Armitage P , et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39
CrossRef | Web of Science | Medline40
Breslow N. Comparison of survival curves. In: Buyse M, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials: methods and practice. Oxford, England: Oxford University Press, 1984:381-406.
41
Breslow N . Analysis of survival data under the proportional hazards model. Int Stat Rev 1975;43:45-58
CrossRef | Web of Science42
Arico M ,Schrappe M ,Harbott J , et al. Prednisone good response (PGR) identifies a subset of t(9;22) childhood acute lymphoblastic leukemia (ALL) at lower risk for early leukemia relapse. Blood 1997;90:Suppl 1:560a-560a abstract.43
Tubergen DG ,Gilchrist GS ,O'Brien RT , et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol 1993;11:520-526
Web of Science | Medline44
Camitta B ,Mahoney D ,Leventhal B , et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1994;12:1383-1389
Web of Science | Medline45
Land VJ ,Shuster JJ ,Crist WM , et al. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1994;12:1939-1945
Web of Science | Medline46
Lange B ,Sather H ,Weetman R , et al. Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia (ALL): a Childrens Cancer Group study, CCG-1891. Blood 1997;90:Suppl 1:559a-559a abstract.
- Citing Articles (142)
Citing Articles
1
Paul S. Gaynon. (2011) A remembrance: James B. Nachman 1948-2011. Pediatric Blood & Cancer 57:4, 533-534
CrossRef2
W. Paul Bowman, Eric L. Larsen, Meenakshi Devidas, Stephen B. Linda, Laurie Blach, Andrew J. Carroll, William L. Carroll, D. Jeanette Pullen, Jonathan Shuster, Cheryl L. Willman, Naomi Winick, Bruce M. Camitta, Stephen P. Hunger, Michael J. Borowitz. (2011) Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906. Pediatric Blood & Cancer 57:4, 569-577
CrossRef3
J. Zhang, C. G. Mullighan, R. C. Harvey, G. Wu, X. Chen, M. Edmonson, K. H. Buetow, W. L. Carroll, I.-M. Chen, M. Devidas, D. S. Gerhard, M. L. Loh, G. H. Reaman, M. V. Relling, B. M. Camitta, W. P. Bowman, M. A. Smith, C. L. Willman, J. R. Downing, S. P. Hunger. (2011) Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 118:11, 3080-3087
CrossRef4
William L. Carroll, Elizabeth A. Raetz. (2011) Clinical and Laboratory Biology of Childhood Acute Lymphoblastic Leukemia. The Journal of Pediatrics
CrossRef5
A. Anoceto Martínez, A. González Otero, E. Guerchicoff de Svarch, A. Arencibia Nuñez, J.C. Jaime, E. Dorticos, S. Sarduy, L. González. (2011) Contaje absoluto de linfocitos como factor pronóstico en la leucemia aguda linfoblástica del niño. Anales de Pediatría
CrossRef6
Paul S. Gaynon. (2011) James B. Nachman, 1948 to 2011. Journal of Pediatric Hematology/Oncology 33:6, 403-405
CrossRef7
B. L. Asselin, M. Devidas, C. Wang, J. Pullen, M. J. Borowitz, R. Hutchison, S. E. Lipshultz, B. M. Camitta. (2011) Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 118:4, 874-883
CrossRef8
Y. Matloub, B. C. Bostrom, S. P. Hunger, L. C. Stork, A. Angiolillo, H. Sather, M. La, J. M. Gastier-Foster, N. A. Heerema, S. Sailer, P. J. Buckley, B. Thomson, C. Cole, J. B. Nachman, G. Reaman, N. Winick, W. L. Carroll, M. Devidas, P. S. Gaynon. (2011) Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 118:2, 243-251
CrossRef9
Fatih M. Uckun, Sanjive Qazi, Zahide Ozer, Amanda L. Garner, Jason Pitt, Hong Ma, Kim D. Janda. (2011) Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. British Journal of Haematology 153:6, 741-752
CrossRef10
Susan O'Brien, Stefan Faderl, Deborah Thomas, Hagop M. Kantarjian. 2011. Acute Lymphoblastic Leukemia. , 228-243.
CrossRef11
D. R. Freyer, M. Devidas, M. La, W. L. Carroll, P. S. Gaynon, S. P. Hunger, N. L. Seibel. (2011) Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood 117:11, 3010-3015
CrossRef12
Karen R. Rabin, M. Monica Gramatges, Michael J. Borowitz, Shana L. Palla, Xiaodong Shi, Judith F. Margolin, Patrick A. Zweidler-McKay. (2011) Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatric Blood & Cancern/a-n/a
CrossRef13
Rajkumar Venkatramani, Larry Wang, Jemily Malvar, Dennis Dias, Richard Sposto, Marcio H. Malogolowkin, Leo Mascarenhas. (2011) Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Pediatric Blood & Cancern/a-n/a
CrossRef14
Hagop M. Kantarjian, Deborah Thomas, Farhad Ravandi, Stefan Faderl, Elias Jabbour, Guillermo Garcia-Manero, Sherry Pierce, Jianquin Shan, Jorge Cortes, Susan O'Brien. (2010) Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116:24, 5568-5574
CrossRef15
R. C. Harvey, C. G. Mullighan, X. Wang, K. K. Dobbin, G. S. Davidson, E. J. Bedrick, I.-M. Chen, S. R. Atlas, H. Kang, K. Ar, C. S. Wilson, W. Wharton, M. Murphy, M. Devidas, A. J. Carroll, M. J. Borowitz, W. P. Bowman, J. R. Downing, M. Relling, J. Yang, D. Bhojwani, W. L. Carroll, B. Camitta, G. H. Reaman, M. Smith, S. P. Hunger, C. L. Willman. (2010) Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116:23, 4874-4884
CrossRef16
W. Stock. (2010) Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Hematology 2010:1, 21-29
CrossRef17
Catriona Parker, Rachel Waters, Carly Leighton, Jeremy Hancock, Rosemary Sutton, Anthony V Moorman, Philip Ancliff, Mary Morgan, Ashish Masurekar, Nicholas Goulden, Nina Green, Tamas Révész, Philip Darbyshire, Sharon Love, Vaskar Saha. (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. The Lancet 376:9757, 2009-2017
CrossRef18
Elizabeth A. Raetz, Wanda L. Salzer. (2010) Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 32:7, 554-563
CrossRef19
James E. Jacobs, Caroline Hastings. (2010) Isolated Extramedullary Relapse in Childhood Acute Lymphocytic Leukemia. Current Hematologic Malignancy Reports 5:4, 185-191
CrossRef20
Susan J. Zunino, David H. Storms, Jonathan M. Ducore. (2010) Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Cancer Letters 296:1, 49-54
CrossRef21
Robert F. Wynn. 2010. Acute Lymphoblastic Leukemia. , 75-94.
CrossRef22
K. W. Maloney, W. L. Carroll, A. J. Carroll, M. Devidas, M. J. Borowitz, P. L. Martin, J. Pullen, J. A. Whitlock, C. L. Willman, N. J. Winick, B. M. Camitta, S. P. Hunger. (2010) Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 116:7, 1045-1050
CrossRef23
Yoshihisa Nagatoshi, Akinobu Matsuzaki, Aiko Suminoe, Hiroko Inada, Kouichiro Ueda, Kiyoshi Kawakami, Fumio Yanai, Hideki Nakayama, Hiroshi Moritake, Nobuyoshi Itonaga, Noriko Hotta, Kyoko Fujita, Yasufumi Hidaka, Takeharu Yamanaka, Yoshifumi Kawano, Jun Okamura. (2010) Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia. Pediatric Blood & Cancer 55:2, 239-247
CrossRef24
R. C. Harvey, C. G. Mullighan, I.-M. Chen, W. Wharton, F. M. Mikhail, A. J. Carroll, H. Kang, W. Liu, K. K. Dobbin, M. A. Smith, W. L. Carroll, M. Devidas, W. P. Bowman, B. M. Camitta, G. H. Reaman, S. P. Hunger, J. R. Downing, C. L. Willman. (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115:26, 5312-5321
CrossRef25
Jennifer L. McNeer, James B. Nachman. (2010) The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. British Journal of Haematology 149:5, 638-652
CrossRef26
Hagop M. Kantarjian, Deborah Thomas, Farhad Ravandi, Stefan Faderl, Guillermo Garcia-Manero, Jianquin Shan, Sherry Pierce, Jorge Cortes, Susan O'Brien. (2010) Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leukemia & Lymphoma 51:3, 475-480
CrossRef27
H. Kang, I.-M. Chen, C. S. Wilson, E. J. Bedrick, R. C. Harvey, S. R. Atlas, M. Devidas, C. G. Mullighan, X. Wang, M. Murphy, K. Ar, W. Wharton, M. J. Borowitz, W. P. Bowman, D. Bhojwani, W. L. Carroll, B. M. Camitta, G. H. Reaman, M. A. Smith, J. R. Downing, S. P. Hunger, C. L. Willman. (2010) Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115:7, 1394-1405
CrossRef28
C Mitchell, S Richards, C J Harrison, T Eden. (2010) Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001. Leukemia 24:2, 406-418
CrossRef29
A Möricke, M Zimmermann, A Reiter, G Henze, A Schrauder, H Gadner, W D Ludwig, J Ritter, J Harbott, G Mann, T Klingebiel, F Zintl, C Niemeyer, B Kremens, F Niggli, D Niethammer, K Welte, M Stanulla, E Odenwald, H Riehm, M Schrappe. (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:2, 265-284
CrossRef30
W L Salzer, M Devidas, W L Carroll, N Winick, J Pullen, S P Hunger, B A Camitta. (2010) Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group. Leukemia 24:2, 355-370
CrossRef31
Rob Pieters, William L. Carroll. (2010) Biology and Treatment of Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 24:1, 1-18
CrossRef32
P S Gaynon, A L Angiolillo, W L Carroll, J B Nachman, M E Trigg, H N Sather, S P Hunger, M Devidas. (2010) Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group Report. Leukemia 24:2, 285-297
CrossRef33
Sima Jeha, Ching-Hon Pui. (2009) Risk-adapted Treatment of Pediatric Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, 973-990
CrossRef34
Deepa Bhojwani, Scott C. Howard, Ching-Hon Pui. (2009) High-Risk Childhood Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma & Leukemia 9:0, S222-S230
CrossRef35
Christopher Mitchell, Jeanette Payne, Rachel Wade, Ajay Vora, Sally Kinsey, Sue Richards, Tim Eden. (2009) The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. British Journal of Haematology 146:4, 424-436
CrossRef36
C. G. Mullighan, J. Zhang, R. C. Harvey, J. R. Collins-Underwood, B. A. Schulman, L. A. Phillips, S. K. Tasian, M. L. Loh, X. Su, W. Liu, M. Devidas, S. R. Atlas, I-M. Chen, R. J. Clifford, D. S. Gerhard, W. L. Carroll, G. H. Reaman, M. Smith, J. R. Downing, S. P. Hunger, C. L. Willman. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences 106:23, 9414-9418
CrossRef37
Lynda M Vrooman, Lewis B Silverman. (2009) Childhood acute lymphoblastic leukemia: update on prognostic factors. Current Opinion in Pediatrics 21:1, 1-8
CrossRef38
Mullighan, Charles G., Su, Xiaoping, Zhang, Jinghui, Radtke, Ina, Phillips, Letha A.A., Miller, Christopher B., Ma, Jing, Liu, Wei, Cheng, Cheng, Schulman, Brenda A., Harvey, Richard C., Chen, I-Ming, Clifford, Robert J., Carroll, William L., Reaman, Gregory, Bowman, W. Paul, Devidas, Meenakshi, Gerhard, Daniela S., Yang, Wenjian, Relling, Mary V., Shurtleff, Sheila A., Campana, Dario, Borowitz, Michael J., Pui, Ching-Hon, Smith, Malcolm, Hunger, Stephen P., Willman, Cheryl L., Downing, James R., the Children's Oncology Group. (2009) Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. New England Journal of Medicine 360:5, 470-480
Full Text39
Martin Stanulla, Martin Schrappe. (2009) Treatment of Childhood Acute Lymphoblastic Leukemia. Seminars in Hematology 46:1, 52-63
CrossRef40
Dan Douer. (2008) Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?. Best Practice & Research Clinical Haematology 21:4, 647-658
CrossRef41
Susan O'Brien, Deborah Thomas, Farhad Ravandi, Stefan Faderl, Jorge Cortes, Gautum Borthakur, Sherry Pierce, Guillermo Garcia-Manero, Hagop M. Kantarjian. (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113:11, 3186-3191
CrossRef42
Susan O'Brien, Deborah A. Thomas, Farhad Ravandi, Stefan Faderl, Sherry Pierce, Hagop Kantarjian. (2008) Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 113:8, 2097-2101
CrossRef43
Hagop Kantarjian, Susan O'Brien, Jorge Cortes, William Wierda, Stefan Faderl, Guillermo Garcia-Manero, Jean-Pierre Issa, Elihu Estey, Michael Keating, Emil J. Freireich. (2008) Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113:S7, 1933-1952
CrossRef44
W. Stock, M. La, B. Sanford, C. D. Bloomfield, J. W. Vardiman, P. Gaynon, R. A. Larson, J. Nachman. (2008) What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 112:5, 1646-1654
CrossRef45
L Charles Bailey, Beverly J Lange, Susan R Rheingold, Nancy J Bunin. (2008) Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. The Lancet Oncology 9:9, 873-883
CrossRef46
Günter Henze. (2008) Early postinduction intensification therapy is essential in childhood acute lymphoblastic leukemia. Nature Clinical Practice Oncology 5:9, 502-503
CrossRef47
Maria Teresa Amparo Buendia H, Juan Manuel Lozano, Gloria Elena Suarez, Carlos Saavedra A, Gonzalo Guevara. (2008) The Impact of Acute Lymphoblastic Leukemia Treatment on Central Nervous System Results in Bogota, Colombia. Journal of Pediatric Hematology/Oncology 30:9, 643-650
CrossRef48
Rebekah C. Allen, Mark T. Holdsworth, Cynthia A. Johnson, Cathy M. Chavez, Richard L. Heideman, Gary Overturf, David Lemon, W. Curtis Hunt, Stuart S. Winter. (2008) Risk determinants for catheter-associated blood stream infections in children and young adults with cancer. Pediatric Blood & Cancer 51:1, 53-58
CrossRef49
M. J. Borowitz, M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll, W. L. Carroll, S. Linda, P. L. Martin, D. J. Pullen, D. Viswanatha, C. L. Willman, N. Winick, B. M. Camitta, . (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111:12, 5477-5485
CrossRef50
Peter D. Cole, Richard A. Drachtman, Margaret Masterson, Angela K. Smith, John Glod, John A. Zebala, Stacey Lisi, Drew-Anne Drapala, Barton A. Kamen. (2008) Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology 62:1, 65-75
CrossRef51
E Fronkova, E Mejstrikova, S Avigad, K W Chik, L Castillo, S Manor, L Reznickova, T Valova, K Zdrahalova, O Hrusak, Y Jabali, M Schrappe, V Conter, S Izraeli, C K Li, B Stark, J Stary, J Trka. (2008) Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?. Leukemia 22:5, 989-997
CrossRef52
A. Moricke, A. Reiter, M. Zimmermann, H. Gadner, M. Stanulla, M. Dordelmann, L. Loning, R. Beier, W.-D. Ludwig, R. Ratei, J. Harbott, J. Boos, G. Mann, F. Niggli, A. Feldges, G. Henze, K. Welte, J.-D. Beck, T. Klingebiel, C. Niemeyer, F. Zintl, U. Bode, C. Urban, H. Wehinger, D. Niethammer, H. Riehm, M. Schrappe, . (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111:9, 4477-4489
CrossRef53
Ching-Hon Pui, Leslie L Robison, A Thomas Look. (2008) Acute lymphoblastic leukaemia. The Lancet 371:9617, 1030-1043
CrossRef54
Michelle J. Henderson, Seoyeon Choi, Alex H. Beesley, David L. Baker, Dale Wright, Rachael A. Papa, Ashleigh Murch, Lynda J. Campbell, Richard B. Lock, Murray D. Norris, Michelle Haber, Ursula R. Kees. (2008) A xenograft model of infant leukaemia reveals a complex MLL translocation. British Journal of Haematology 140:6, 716-719
CrossRef55
N. L. Seibel, P. G. Steinherz, H. N. Sather, J. B. Nachman, C. DeLaat, L. J. Ettinger, D. R. Freyer, L. A. Mattano, C. A. Hastings, C. M. Rubin, K. Bertolone, J. L. Franklin, N. A. Heerema, T. L. Mitchell, A. F. Pyesmany, M. K. La, C. Edens, P. S. Gaynon. (2008) Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 111:5, 2548-2555
CrossRef56
A. von Stackelberg, R. Hartmann, C. Buhrer, R. Fengler, G. Janka-Schaub, A. Reiter, G. Mann, K. Schmiegelow, R. Ratei, T. Klingebiel, J. Ritter, G. Henze, . (2008) High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood 111:5, 2573-2580
CrossRef57
Rob Pieters, William L. Carroll. (2008) Biology and Treatment of Acute Lymphoblastic Leukemia. Pediatric Clinics of North America 55:1, 1-20
CrossRef58
Guillermo De Angulo, Carrie Yuen, Shana L. Palla, Peter M. Anderson, Patrick A. Zweidler-McKay. (2008) Absolute lymphocyte count is a novel prognostic indicator in ALL and AML. Cancer 112:2, 407-415
CrossRef59
Fatih M. Uckun. (2008) Clinical Potential of Targeting Bruton's Tyrosine Kinase. International Reviews of Immunology 27:1-2, 43-69
CrossRef60
Michael E. Trigg, Harland N. Sather, Gregory H. Reaman, David G. Tubergen, Peter G. Steinherz, Paul S. Gaynon, Fatih M. Uckun, G. Denman Hammond. (2008) Ten-year survival of children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. Leukemia & Lymphoma 49:6, 1142-1154
CrossRef61
Jong Hyung Yoon, Eun Kyung Kim, Jeong Ah Park, Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn. (2008) Effect of Treatment Modification by the Initial Response in Patients with High-Risk Childhood Acute Lymphoblastic Leukemia. The Korean Journal of Hematology 43:4, 238
CrossRef62
N. L. Seibel. (2008) Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents: Peaks and Pitfalls. Hematology 2008:1, 374-380
CrossRef63
Julie E. Chang, Stephen C. Medlin, Brad S. Kahl, Walter L. Longo, Eliot C. Williams, Jack Lionberger, Kyungmann Kim, Jihoon Kim, Elizabeth Esterberg, Mark B. Juckett. (2008) Augmented and standard Berlin–Frankfurt–Münster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leukemia & Lymphoma 49:12, 2298-2307
CrossRef64
James Nachman. (2008) The courage to change. Leukemia & Lymphoma 49:6, 1026-1027
CrossRef65
M. H. Kang, Y. H. Kang, B. Szymanska, U. Wilczynska-Kalak, M. A. Sheard, T. M. Harned, R. B. Lock, C. P. Reynolds. (2007) Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110:6, 2057-2066
CrossRef66
André Baruchel. (2007) Adolescents and young adults with acute lymphoblastic leukaemia: A new frontier?. European Journal of Cancer Supplements 5:5, 203-208
CrossRef67
Barton A. Kamen. (2007) L??Asparaginase and Methotrexate Combinations: Clashes of Empiric Success and Laboratory Models?. Journal of Pediatric Hematology/Oncology 29:9, 587-588
CrossRef68
S. S. Winter, Z. Jiang, H. M. Khawaja, T. Griffin, M. Devidas, B. L. Asselin, R. S. Larson. (2007) Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 110:5, 1429-1438
CrossRef69
Wanda L. Salzer, Meenakshi Devidas, Jonathan J. Shuster, Chenguang Wang, Allen Chauvenet, Barbara L. Asselin, Bruce M. Camitta, Joanne Kurtzberg. (2007) Intensified PEG-L-asparaginase and Antimetabolite-based Therapy for Treatment of Higher Risk Precursor-B Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 29:6, 369-375
CrossRef70
Nicholas G. Gottardo, Katrin Hoffmann, Alex H. Beesley, Joseph R. Freitas, Martin J. Firth, Kanchana U. Perera, Nicolas H. de Klerk, David L. Baker, Ursula R. Kees. (2007) Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia. British Journal of Haematology 137:4, 319-328
CrossRef71
Vassilios I. Avramis, Susan A. Spence. (2007) Clinical Pharmacology of Asparaginases in the United States: Asparaginase Population Pharmacokinetic and Pharmacodynamic (PK-PD) Models (NONMEM) in Adult and Pediatric ALL Patients. Journal of Pediatric Hematology/Oncology 29:4, 239-247
CrossRef72
N.-G. Chung, V. Buxhofer-Ausch, J. P. Radich. (2006) The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens 68:5, 371-385
CrossRef73
Ajay Vora, Chris D Mitchell, Lynne Lennard, TOB Eden, Sally E Kinsey, John Lilleyman, Sue M Richards. (2006) Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. The Lancet 368:9544, 1339-1348
CrossRef74
Peter L. Bonate, Larry Arthaud, William R. Cantrell, Katherine Stephenson, John A. Secrist, Steve Weitman. (2006) Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nature Reviews Drug Discovery 5:10, 855-863
CrossRef75
Elizabeth A. Raetz, William L. Carroll. (2006) Eliminating a gold standard in childhood acute lymphoblastic leukemia?. Pediatric Blood & Cancer 47:3, 242-244
CrossRef76
Janet L. Franklin, Jonathan Finlay. (2006) Leukemias and lymphomas: Treatment and prophylaxis of the central nervous system. Current Treatment Options in Neurology 8:4, 335-345
CrossRef77
Élie Azoulay, Benoît Schlemmer. (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Medicine 32:6, 808-822
CrossRef78
Pui, Ching-Hon, Evans, William E., . (2006) Treatment of Acute Lymphoblastic Leukemia. New England Journal of Medicine 354:2, 166-178
Full Text79
Michael Darmon, Guillaume Thiery, Magali Ciroldi, Sandra de Miranda, Lionel Galicier, Emmanuel Raffoux, Jean-Roger Le Gall, Beno??t Schlemmer, ??lie Azoulay. (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy*. Critical Care Medicine 33:11, 2488-2493
CrossRef80
Elizabeth A Raetz, Deepa Bhojwani, Dong-Joon Min, William L Carroll. (2005) Individualized therapy for childhood acute lymphoblastic leukemia. Personalized Medicine 2:4, 349-361
CrossRef81
Adriana Balduzzi, Maria Grazia Valsecchi, Cornelio Uderzo, Paola De Lorenzo, Thomas Klingebiel, Christina Peters, Jan Stary, Maria S Felice, Edina Magyarosy, Valentino Conter, Alfred Reiter, Chiara Messina, Helmut Gadner, Martin Schrappe. (2005) Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. The Lancet 366:9486, 635-642
CrossRef82
M Aricó, A Baruchel, Y Bertrand, A Biondi, V Conter, T Eden, H Gadner, P Gaynon, K Horibe, S P Hunger, G Janka-Schaub, G Masera, J Nachman, R Pieters, M Schrappe, K Schmiegelow, M G Valsecchi, C-H Pui. (2005) The Seventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Palermo, Italy, January 29–30, 2005. Leukemia 19:7, 1145-1152
CrossRef83
Deborah D. Kennedy, Elena J. Ladas, Susan R. Rheingold, Jeffrey Blumberg, Kara M. Kelly. (2005) Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Pediatric Blood & Cancer 44:4, 378-385
CrossRef84
Akira Morimoto, Kikuko Kuriyama, Shigeyoshi Hibi, Shinjiro Todo, Takao Yoshihara, Hiroshi Kuroda, Shinsaku Imashuku. (2005) Prognostic Value of Early Response to Treatment Combined with Conventional Risk Factors in Pediatric Acute Lymphoblastic Leukemia. International Journal of Hematology 81:3, 228-234
CrossRef85
William L. Carroll, Elizabeth A. Raetz. (2005) Building better therapy for children with acute lymphoblastic leukemia. Cancer Cell 7:4, 289-291
CrossRef86
Anindita Roy, Mike Bradburn, Anthony V. Moorman, Julie Burrett, Sharon Love, Sally E. Kinsey, Chris Mitchell, Ajay Vora, Tim Eden, John S. Lilleyman, Ian Hann, Vaskar Saha, . (2005) Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. British Journal of Haematology 129:1, 35-44
CrossRef87
V M Whitehead, J J Shuster, M J Vuchich, D H Mahoney, S J Lauer, C Payment, P A Koch, L D Cooley, A T Look, D J Pullen, B Camitta. (2005) Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia
CrossRef88
Gaston K. Rivera, Yinmei Zhou, Michael L. Hancock, Amar Gajjar, Jeffrey Rubnitz, Raul C. Ribeiro, John T. Sandlund, Melissa Hudson, Mary Relling, William E. Evans, Ching-Hon Pui. (2005) Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 103:2, 368-376
CrossRef89
Vassilios I Avramis, Eduard H Panosyan. (2005) Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations. Clinical Pharmacokinetics 44:4, 367-393
CrossRef90
Hagop Kantarjian, Deborah Thomas, Susan O'Brien, Jorge Cortes, Francis Giles, Sima Jeha, Carlos E. Bueso-Ramos, Sherry Pierce, Jianqin Shan, Charles Koller, Miloslav Beran, Michael Keating, Emil J. Freireich. (2004) Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101:12, 2788-2801
CrossRef91
Parinda A Mehta, Stella M Davies. (2004) Pharmacogenetics of acute lymphoblastic leukemia. Current Opinion in Hematology 11:6, 434-438
CrossRef92
Blythe Thomson, Julie R. Park, Judy Felgenhauer, Soheil Meshinchi, John Holcenberg, J. Russell Geyer, Vassilios Avramis, James G. Douglas, Michael R. Loken, Douglas S. Hawkins. (2004) Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatric Blood & Cancer 43:5, 571-579
CrossRef93
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Huang, Mary S., Hasserjian, Robert P., . (2004) Case 19-2004. New England Journal of Medicine 350:25, 2604-2612
Full Text94
Barton A. Kamen. (2004) High-Dose Methotrexate and Asparaginase for the Treatment of Children With Acute Lymphoblastic Leukemia: Why and How?. Journal of Pediatric Hematology/Oncology 26:6, 333-335
CrossRef95
John Holcenberg. (2004) Optimal Asparaginase Therapy. Journal of Pediatric Hematology/Oncology 26:5, 273-274
CrossRef96
Eduard H. Panosyan, Nita L. Seibel, Sagrario Martin-Aragon, Paul S. Gaynon, Ioannis A. Avramis, Harland Sather, Janet Franklin, James Nachman, Lawrence J. Ettinger, Mei La, Peter Steinherz, Lewis J. Cohen, Stuart E. Siegel, Vassilios I. Avramis. (2004) Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 26:4, 217-226
CrossRef97
Ulla M. Saarinen-Pihkala, G. Gustafsson, N. Carlsen, T. Flaegstad, E. Forestier, A. Glomstein, J. Kristinsson, M. Lanning, H. Schroeder, L. Mellander, . (2004) Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatric Blood & Cancer 42:1, 8-23
CrossRef98
Paul C. Nathan, Ronnen Maze, Brenda Spiegler, Mark L. Greenberg, Sheila Weitzman, Johann K. Hitzler. (2004) CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation. Pediatric Blood & Cancer 42:1, 24-29
CrossRef99
Jeanette H. Payne, Jennifer C. Welch, Ajay J. Vora. (2003) Fatal Pulmonary Hemorrhage Associated With Micrococcal Infection in Two Children With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 25:12, 969-974
CrossRef100
Martin Schrappe. (2003) Prognostic factors in childhood acute lymphoblastic leukemia. The Indian Journal of Pediatrics 70:10, 817-824
CrossRef101
M.Fatih Okcu, W.Mark Roberts, Dennis A. Johnston, Maia V. Ouspenskaia, Victor Z. Papusha, Mark A. Brandt, Theodore F. Zipf. (2003) Risk classification at the time of diagnosis differentially affects the level of residual disease in children with B-precursor acute lymphoblastic leukemia after completion of therapy. Leukemia Research 27:8, 743-750
CrossRef102
E.J Estlin, G.J Veal. (2003) Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treatment Reviews 29:4, 253-273
CrossRef103
Lewis B. Silverman, Stephen E. Sallan. (2003) Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Current Opinion in Hematology 10:4, 290-296
CrossRef104
Jean Delorme, Stéphanie Badin, Anne-Gaelle G. Le Corroller, Anne Aurtignon Auvrignon, Marie-Françoise Auclerc, Virginie Gandemer, Pierre Bordigoni, Jean-Pierre Lamagnere, François Demeocq, Yves Perel, Christian Berthou, François Bauduer, Brigitte Pautard, Jean-Pierre Vannier, Diane Braguer, Thierry Leblanc, Guy Leverger, André Baruchel, Gérard Michel. (2003) Economic Evaluation of Recombinant Human Granulocyte Colony-Stimulating Factor in Very High-Risk Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 25:6, 441-447
CrossRef105
Ugur Ozbek, Sema Sirma, Leyla Agaoglu, Lebriz Yuksel, Sema Anak, Inci Yildiz, Omer Devecioglu, Cetin Timur, Adalet Meral, Gunduz Gedikoglu. (2003) Prognostic Significance of the TEL-AML1 Fusion Gene in Pediatric Acute Lymphoblastic Leukemia in Turkey. Journal of Pediatric Hematology/Oncology 25:3, 204-208
CrossRef106
C. K. LI, K. W. Chik, G. C. F. Chan, H. L. Yuen, A. C. W. Lee, C. Keung Li, M. M. K. Shing, S. Y. Ha, C. W. Luk, S. C. Ling, A. Y. K. Cheung, . (2003) Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study. Hematological Oncology 21:1, 1-9
CrossRef107
Robert J. Arceci. (2003) Comments From the Editor-in-Chief. Journal of Pediatric Hematology/Oncology 25:2, 97-98
CrossRef108
Martin Schrappe, Rita Beier, Britta Bürger. (2002) New treatment strategies in childhood acute lymphoblastic leukaemia. Best Practice & Research Clinical Haematology 15:4, 729-740
CrossRef109
James B. Nachman. (2002) Treatment: The Most Important Prognostic Variable. Journal of Pediatric Hematology/Oncology 24:9, 704-705
CrossRef110
Elpis Mantadakis, Angela K. Smith, Linda Hynan, Naomi J. Winick, Barton A. Kamen. (2002) Methotrexate Polyglutamation May Lack Prognostic Significance in Children With B-Cell Precursor Acute Lymphoblastic Leukemia Treated With Intensive Oral Methotrexate. Journal of Pediatric Hematology/Oncology 24:8, 636-642
CrossRef111
Tim Eden. (2002) Translation of Cure for Acute Lymphoblastic Leukaemia to all Children. British Journal of Haematology 118:4, 945-951
CrossRef112
Paul S. Gaynon. (2002) Response to Donadieu and Hill. Journal of Pediatric Hematology/Oncology 24:6, 426-428
CrossRef113
Judith M. Chessells, Georgina Harrison, Susan M. Richards, Brenda E. Gibson, Clifford C. Bailey, Frank G. H. Hill, Ian M. Hann, , Research Council Working Party on Childhood Leukaemia. (2002) Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. British Journal of Haematology 118:2, 445-455
CrossRef114
Ching-Hon Pui, Mary V. Relling, Dario Campana, William E. Evans. (2002) Childhood acute lymphoblastic leukemia. Reviews in Clinical and Experimental Hematology 6:2, 161-180
CrossRef115
Thomas A. Kaleita. (2002) Central nervous system-directed therapy in the treatment of childhood acute lymphoblastic leukemia and studies of neurobehavioral outcome: children’s cancer group trials. Current Oncology Reports 4:2, 131-141
CrossRef116
Paul S. Gaynon. (2002) From Where Do Clinical Trials Come?. Journal of Pediatric Hematology/Oncology 24:3, 172-174
CrossRef117
Nyla A. Heerema, Harland N. Sather, Martha G. Sensel, Mei K. L. La, Raymond J. Hutchinson, James B. Nachman, Gregory H. Reaman, Beverly J. Lange, Peter G. Steinherz, Bruce C. Bostrom, Paul S. Gaynon, Fatih M. Uckun. (2002) Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer 94:4, 1102-1110
CrossRef118
Tomomi Okamoto, Shouhei Yokota, Naoyuki Katano, Taku Seriu, Makoto Nakao, Masafumi Taniwaki, Arata Watanabe, Keiko Asami, Atsushi Kikuta, Shoichi Koizumi, Tetsuo Kawakami, Shigeru Ohta, Munenori Miyake, Tsutomu Watanabe, Asayuki Iwai, Akira Kamitamari, Osamu Ijichi, Nobuyuki Hyakuna, Junichi Mimaya, Takeo Fujimoto, Masahito Tsurusawa. (2002) Minimal Residual Disease in Early Phase of Chemotherapy Reflects Poor Outcome in Children With Acute Lymphoblastic Leukemia--A Retrospective Study by the Children's Cancer and Leukemia Study Group in Japan. Leukemia & Lymphoma 43:5, 1001-1006
CrossRef119
Soheil Meshinchi, Blythe Thomson, Laura S. Finn, Wendy Leisenring, Cheri Green, Jerald P. Radich, Michael Loken, Douglas Hawkins. (2001) Comparison of Multidimensional Flow Cytometry With Standard Morphology for Evaluation of Early Marrow Response in Pediatric Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 23:9, 585-590
CrossRef120
E.J Estlin. (2001) Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Cancer Treatment Reviews 27:6, 351-363
CrossRef121
E.J. Estlin, S.M. Yule, S.P. Lowis. (2001) Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide. Cancer Treatment Reviews 27:6, 339-350
CrossRef122
Taijiro Mori, Atsushi Manabe, Masahiro Tsuchida, Ryoji Hanada, Hiromasa Yabe, Akira Ohara, Tomohiro Saito, Shinpei Nakazawa. (2001) Allogeneic bone marrow transplantation in first remission rescues children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) studies L89-12 and L92-13. Medical and Pediatric Oncology 37:5, 426-431
CrossRef123
Fernando Marco, Encarna Bureo, Arancha Bermúdez, Elena Fernández-Fontecha, Alberto Zubizarreta. (2001) Treatment of acute leukemia in children: recent advances and future challenges. Expert Review of Anticancer Therapy 1:3, 479-486
CrossRef124
Ching-Hon Pui, Dario Campana, William E Evans. (2001) Childhood acute lymphoblastic leukaemia – current status and future perspectives. The Lancet Oncology 2:10, 597-607
CrossRef125
Junichi Hara, Yong-Dong Park, Akira Yoshioka, Keiko Yumura-Yagi, Urara Koudera, Gaku Hosoi, Masahiro Sako, Yoshiyuki Kosaka, Kimihiko Sano, Hideo Misu, Osamu Mabuchi, Noriyuki Aoyagi, Masuji Yamamoto, Akio Tawa, Hiroshi Miyata, Haruki Tanaka, Makiko Kikkawa, Mutsuro Shimodera, Keisei Kawa-Ha. (2001) Intensification of Chemotherapy Using Block Therapies as Consolidation and Reinduction Therapies for Acute Lymphoblastic Leukemia During Childhood. International Journal of Hematology 74:2, 165-172
CrossRef126
Eiichi Ishii, Haruhiko Eguchi, Akinobu Matsuzaki, Hiroyuki Koga, Fumio Yanai, Hiroshi Kuroda, Kiyoshi Kawakami, Hiroshi Ayukawa, Kensuke Akiyoshi, Junji Kamizono, Yuji Tamai, Naoko Kinukawa, Jun Okamura. (2001) Outcome of acute lymphoblastic leukemia in children with AL90 regimen: Impact of response to treatment and sex difference on prognostic factors. Medical and Pediatric Oncology 37:1, 10-19
CrossRef127
Ian Hann, Ajay Vora, Georgina Harrison, Christine Harrison, Osborn Eden, Frank Hill, Brenda Gibson, Sue Richards, . (2001) Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. British Journal of Haematology 113:1, 103-114
CrossRef128
Nick Goulden, Anthony Oakhill, Colin Steward. (2001) Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Annotation. British Journal of Haematology 112:2, 275-281
CrossRef129
Fatih M. Uckun, Paul S. Gaynon, Daniel O. Stram, Martha G. Sensel, Mireille B. Sarquis, Michael Willoughby. (2001) Bone Marrow Leukemic Progenitor Cell Content in Pediatric T-Lineage Acute Lymphoblastic Leukemia Patients with an Isolated Extramedullar First Relapse. Leukemia & Lymphoma 40:3-4, 279-285
CrossRef130
E. J. Estlin, M. Ronghe, G. A. A. Burke, S. M. Yule. (2000) The Clinical and Cellular Pharmacology Of Vincristine, Corticosteroids, l-Asparaginase, Anthracyclines and Cyclophosphamide In Relation To Childhood Acute Lymphoblastic Leukaemia. British Journal of Haematology 110:4, 780-790
CrossRef131
Regina M. Vidaver, Bonnie Lafleur, Cynthia Tong, Robynne Bradshaw, Sherry A. Marts. (2000) Women Subjects in NIH-Funded Clinical Research Literature: Lack of Progress in Both Representation and Analysis by Sex. Journal of Women's Health & Gender-Based Medicine 9:5, 495-504
CrossRef132
Ann M. Leahey, Nancy J. Bunin, Jean B. Belasco, Rita Meek, Charles Scher, Beverly J. Lange. (2000) Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia. Medical and Pediatric Oncology 34:5, 313-318
CrossRef133
Nyla A. Heerema, Harland N. Sather, Martha G. Sensel, Mei K. Lee, Raymond Hutchinson, James B. Nachman, Beverly J. Lange, Peter G. Steinherz, Bruce Bostrom, Paul S. Gaynon, Fatih M. Uckun. (2000) Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia. Cancer 88:8, 1945-1954
CrossRef134
Aricò, Maurizio, Valsecchi, Maria Grazia, Camitta, Bruce, Schrappe, Martin, Chessells, Judith, Baruchel, André, Gaynon, Paul, Silverman, Lewis, Janka-Schaub, Gritta, Kamps, Willem, Pui, Ching-Hon, Conter, V., Riehm, H., Heerema, N., Sallan, S., Pullen, J., Shuster, J., Carroll, A., Raimondi, S., Richards, S., Masera, Giuseppe, . (2000) Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. New England Journal of Medicine 342:14, 998-1006
Full Text135
David A Perrey, Rama Krishna Narla, Fatih M Uckun. (2000) Cysteine chloromethyl and diazomethyl ketone derivatives with potent anti-leukemic activity. Bioorganic & Medicinal Chemistry Letters 10:6, 547-549
CrossRef136
Chessells. (2000) THE MANAGEMENT OF HIGH-RISK LYMPHOBLASTIC LEUKAEMIA IN CHILDREN. British Journal of Haematology 108:2, 204-216
CrossRef137
Ching-Hon Pui. (2000) Acute lymphoblastic leukemia in children. Current Opinion in Oncology 12:1, 3-12
CrossRef138
O. B. Eden. (1999) Acute lymphoblastic leukaemia: Whom and when should we transplant?. Pediatric Transplantation 3, 108-115
CrossRef139
Lewis B. Silverman, Richard D. Gelber, Mary L. Young, Virginia Kimball Dalton, Ronald D. Barr, Stephen E. Sallan. (1999) Induction failure in acute lymphoblastic leukemia of childhood. Cancer 85:6, 1395-1404
CrossRef140
(1999) Detection of Residual Disease in Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine 340:2, 152-154
Full Text141
(1998) Augmented Post-Induction Therapy in Childhood Lymphoblastic Leukemia. New England Journal of Medicine 339:15, 1080-1081
Full Text142
Wood, Alastair J.J., , Pui, Ching-Hon, Evans, William E., . (1998) Acute Lymphoblastic Leukemia. New England Journal of Medicine 339:9, 605-615
Full Text
- Letters
